Literature DB >> 23632325

Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.

Michael Silver1, Stewart A Factor.   

Abstract

BACKGROUND: Valproic acid is a drug used for the treatment of a variety of psychiatric and neurological disorders. While it is well known to cause postural tremor, hyperammonemia, slowness, and sedation, it has also been described to occasionally cause a reversible form of parkinsonism.
MATERIALS AND METHODS: A series of five cases is reported.
RESULTS: All patients were taking the drug for at least several months before onset of their parkinsonian symptoms. Parkinsonism was defined by the presence of bradykinesia, rigidity, postural instability, and resting tremor, but not postural or action tremor. After discontinuing their valproic acid, improvement was seen by all patients. The course of improvement took days to months after discontinuance. Two of these patients responded to dopaminergic therapy, with drug-induced dyskinesia observed in one. In another patient, valproic acid was thought to unmask underlying Parkinson's Disease; this patient benefited from levodopa as well.
CONCLUSION: Valproic acid-induced parkinsonism can look identical to idiopathic parkinsonism. In all five cases, the relationship between the valproic acid use and parkinsonism was initially unclear because of the delayed and insidious onset. Our finding of levodopa responsiveness and dyskinesia added to the diagnostic confusion. This treatment responsiveness also set it apart from neuroleptic-induced parkinsonism. In all cases improvement of symptoms occurred after discontinuation of the offending medication.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23632325     DOI: 10.1016/j.parkreldis.2013.03.016

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  FTLD Treatment: Current Practice and Future Possibilities.

Authors:  Peter A Ljubenkov; Adam L Boxer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.

Authors:  Daniel A Gorman; David M Gardner; Andrea L Murphy; Mark Feldman; Stacey A Bélanger; Margaret M Steele; Khrista Boylan; Kate Cochrane-Brink; Roxanne Goldade; Paul R Soper; Judy Ustina; Tamara Pringsheim
Journal:  Can J Psychiatry       Date:  2015-02       Impact factor: 4.356

3.  Can Valproic Acid Regulate Neurogenesis from Nestin+ Cells in the Adult Midbrain?

Authors:  Parisa Farzanehfar; Malcolm K Horne; Tim D Aumann
Journal:  Neurochem Res       Date:  2017-04-22       Impact factor: 3.996

Review 4.  Valproate-Associated Parkinsonism: A Critical Review of the Literature.

Authors:  Florian Brugger; Kailash P Bhatia; Frank M C Besag
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 5.  Treatment of myoclonus.

Authors:  John N Caviness
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 6.  Insights into Pathophysiology from Medication-induced Tremor.

Authors:  John C Morgan; Julie A Kurek; Jennie L Davis; Kapil D Sethi
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-11-22

7.  Non-hyperammonaemic valproate encephalopathy after 20 years of treatment.

Authors:  Elizabeth Caruana Galizia; Jeremy D Isaacs; Hannah R Cock
Journal:  Epilepsy Behav Case Rep       Date:  2017-04-21

Review 8.  Parkinsonism: A Rare Adverse Effect of Valproic Acid.

Authors:  Abilash Muralidharan; Jawaria Rahman; Dipanjan Banerjee; Abdul Rub Hakim Mohammed; Bilal Haider Malik
Journal:  Cureus       Date:  2020-06-23

9.  Acute dyskinesia, myoclonus, and akathisa in an adolescent male abusing quetiapine via nasal insufflation: a case study.

Authors:  Mathew George; Maya Haasz; Alvaro Coronado; Steven Salhanick; Lindsey Korbel; Joseph P Kitzmiller
Journal:  BMC Pediatr       Date:  2013-11-16       Impact factor: 2.125

Review 10.  Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease.

Authors:  Srinivasa Reddy Bonam; Christine Tranchant; Sylviane Muller
Journal:  Cells       Date:  2021-12-15       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.